Table 3.
Interaction between family history of cancer and first-line platinum therapy
| Number at risk | Number of deaths |
Median overall survival (95 % CI) |
Adjusted hazard ratioa for stratified models (95 % CI) |
Adjusted stratified p valuea |
Adjusted inter- action p valuea |
|
|---|---|---|---|---|---|---|
| No family history of breast, ovarian, or pancreatic cancer | ||||||
| No first-line platinum | 198 | 176 | 8.4 (7.5–10.1) | 1 | 0.005 | 0.017 |
| First-line platinum | 151 | 135 | 7.3 (6.1–8.6) | 1.42 (1.11–1.80) | ||
| Family history of breast, ovarian, or pancreatic cancer | ||||||
| No first-line platinum | 93 | 83 | 7.9 (6.8–10.4) | 1 | 0.314 | |
| First-line platinum | 107 | 94 | 9.1 (7.5–11.5) | 0.85 (0.61–1.18) | ||
| No pedigree history of breast, ovarian, or pancreatic cancer | ||||||
| No first-line platinum | 194 | 172 | 8.3 (7.5–10.0) | 1 | 0.008 | 0.047 |
| First-line platinum | 147 | 131 | 7.3 (6.1–8.8) | 1.39 (1.08–1.77) | ||
| Pedigree history of breast, ovarian, or pancreatic cancer | ||||||
| No first-line platinum | 97 | 87 | 8.1 (6.8–10.5) | 1 | 0.474 | |
| First-line platinum | 111 | 98 | 8.8 (7.5–10.8) | 0.89 (0.64–1.23) | ||
| No family history of cancer | ||||||
| No first-line platinum | 71 | 63 | 8.2 (7.4–10.7) | 1 | 0.013 | 0.101 |
| First-line platinum | 51 | 46 | 5.0 (4.2–8.1) | 1.74 (1.12–2.71) | ||
| Family history of cancer | ||||||
| No first-line platinum | 220 | 196 | 8.3 (7.3–10.1) | 1 | 0.384 | |
| First-line platinum | 207 | 183 | 8.5 (7.4–10.3) | 1.10 (0.88–1.37) | ||
a
Models are adjusted for age, African-American race, liver metastases, and cohort (JHH vs. MDA)